Patents by Inventor Keld Dan.o slashed.

Keld Dan.o slashed. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6113897
    Abstract: A monoclonal or polyclonal antibody directed against urokinase plasminogen activator receptor (u-PAR), or a subsequence, analogue or glycosylation variant thereof. Antibodies are disclosed which react with free u-PAR or with complexes between u-PA and u-PAR and which are capable of 1) catching u-PAR in ELISA, or 2) detecting u-PAR, e.g. in blotting, or 3) in radioimmunoprecipitation assay precipitate purified u-PAR in intact or fragment form, or 4) is useful for immunohistochemical detection of u-PAR, e.g. in immunostaining of cancer cells, such as in tissue sections at the invasive front, or 5) inhibits the binding of pro-u-PA and active u-PA and thereby inhibits cell surface plasminogen activation. Methods are disclosed 1) for detecting or quantifying u-PAR, 2) for targeting a diagnostic to a cell containing a u-PAR on the surface, 3) for preventing or counteracting proteolytic activity in a mammal.
    Type: Grant
    Filed: December 28, 1995
    Date of Patent: September 5, 2000
    Assignee: Cancerforskiningsfonden af 1989
    Inventors: Keld Dan.o slashed., Ebbe R.o slashed.nne, Niels Behrendt, Vincent Ellis, Gunilla H.o slashed.yer-Hansen, Charles Pyke, Nils Bruenner
  • Patent number: 6025142
    Abstract: The invention relates to an antibody which inhibits the binding between u-PA and u-PAR to an extent of at least 90% in an assay as defined in the specification, or an active fragment or immunological equivalent of said antibody. Examples of such antibodies are deposited Jul. 7, 1994 at Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSM) with accession numbers DSM ACC2178 and DSM ACC2179 under the terms and conditions of the Budapest Treaty. The invention furthermore relates to a method for detecting or quantifying u-PAR or a glycosylation variant of u-PAR in a sample by use of an antibody according to the invention.Furthermore, the invention relates to a method for the manufacture of a therapeutic agent for preventing or counteracting localized proteolytic activity using of an antibody of the invention as well as to use of an antibody according to the invention for the preparation of a diagnostic agent which is capable of targeting a diagnostic to a cell that contains a u-PAR on the surface.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: February 15, 2000
    Assignees: Boehringer Mannheim GmbH, Cancerforskningsfonden af 1989
    Inventors: Ulrich Pessara, Ulrich Weidle, Bernhard Konig, Ulrich Kohnert, Ilse Bartke, Keld Dan.o slashed., Michael Ploug, Vincent Ellis
  • Patent number: 5891664
    Abstract: Activation of plasminogen to plasma is inhibited by preventing the binding of a receptor binding form of urokinase-type plasminogen activator to a urokinase-type plasminogen activator receptor in a mammal, thereby preventing the urokinase-type plasminogen activator from converting plasminogen into plasmin. DNA fragments which encode for soluble, active fragments of the urokinase-type plasminogen activator are provided.
    Type: Grant
    Filed: October 6, 1994
    Date of Patent: April 6, 1999
    Assignee: Cancerforskningsfondet af 1989
    Inventors: Keld Dan.o slashed., Francesco Blasi, Ann Louring Roldan, Maria Vittoria Cubellis, Maria Teresa Masucci, Ettore Appella, Wolf-Dieter Schleuning, Niels Behrendt, Ebbe R.o slashed.nne, Peter Kristensen, Jari Pollanen, Eeva-Marjatta Salonen, Ross W. Stephens, Hannele Tapiovaara, Antti Vaheri, Lisbeth Birk M.o slashed.ller, Vincent Ellis, Leif R.o slashed.ge Lund, Michael Ploug, Charles Pyke, Laszlo Patthy